It is reported that the inhibition of DGAT1 is a promising strategy for the treatment of obesity and type 2 diabetes in order to attenuate excessive lipid biosynthesis and deposit [23, 24]. This evidence concerns the gene DGAT1 and obesity due to melanocortin 4 receptor deficiency.